{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:27:18Z","timestamp":1792672038119,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60119-3","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:27:08Z","timestamp":1751354828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Jingjing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9750-7518","authenticated-orcid":false,"given":"Junrong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-1792","authenticated-orcid":false,"given":"Yang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-1992","authenticated-orcid":false,"given":"Yuhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinbao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6549-9605","authenticated-orcid":false,"given":"Weijing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-1242","authenticated-orcid":false,"given":"Jieer","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"60119_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"60119_CR2","first-page":"221","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng, R. S. et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi 46, 221\u2013231 (2024).","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"60119_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med."},{"key":"60119_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","volume":"40","author":"D-Y Oh","year":"2022","unstructured":"Oh, D.-Y. et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J. Clin. Oncol. 40, 378 (2022).","journal-title":"J. Clin. Oncol."},{"key":"60119_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle, M. et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol. Hepatol. 6, 803\u2013815 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"60119_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal, L. et al. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N. Engl. J. Med. 388, 228\u2013239 (2023).","journal-title":"N. Engl. J. Med."},{"key":"60119_CR7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu, A. X. et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma With IDH1 mutation: the phase 3 randomized cLINical ClarIDHy trial. JAMA Oncol. 7, 1669\u20131677 (2021).","journal-title":"JAMA Oncol."},{"key":"60119_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684 (2020).","journal-title":"Lancet Oncol."},{"key":"60119_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","volume":"8","author":"CK Lee","year":"2023","unstructured":"Lee, C. K. et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol. Hepatol. 8, 56\u201365 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"60119_CR10","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah, V. et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 21, 1234\u20131243 (2020).","journal-title":"Lancet Oncol."},{"key":"60119_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele, R. C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 271\u2013282 (2020).","journal-title":"Lancet Oncol."},{"key":"60119_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding, J. J. et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 24, 772\u2013782 (2023).","journal-title":"Lancet Oncol."},{"key":"60119_CR13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/JCO.23.01193","volume":"42","author":"V Ostwal","year":"2024","unstructured":"Ostwal, V. et al. Trastuzumab plus gemcitabine-cisplatin for treatment-naive human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB). J. Clin. Oncol. 42, 800\u2013807 (2024).","journal-title":"J. Clin. Oncol."},{"key":"60119_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y. & Zhu, A. X. Biliary tract cancer. Lancet 397, 428\u2013444 (2021).","journal-title":"Lancet"},{"key":"60119_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno, M. et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol. Hepatol. 4, 611\u2013621 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"60119_CR16","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul, S. A. et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int. J. Cancer 147, 2190\u20132198 (2020).","journal-title":"Int. J. Cancer"},{"key":"60119_CR17","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1200\/JCO.2022.40.16_suppl.4108","volume":"40","author":"M Delaye","year":"2022","unstructured":"Delaye, M. et al. Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): Interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study. J. Clin. Oncol. 40, 4108\u20134108 (2022).","journal-title":"J. Clin. Oncol."},{"key":"60119_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol. Hepatol. 7, 522\u2013532 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"60119_CR19","doi-asserted-by":"crossref","unstructured":"Chen, X. et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J. Immunother. Cancer 8, e001240 (2020).","DOI":"10.1136\/jitc-2020-001240"},{"key":"60119_CR20","doi-asserted-by":"crossref","unstructured":"Feng, K. et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J. Immunother. Cancer 8, e000367 (2020).","DOI":"10.1136\/jitc-2019-000367"},{"key":"60119_CR21","doi-asserted-by":"crossref","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865 (2023).","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"60119_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.tips.2019.07.001","volume":"40","author":"Z Liu","year":"2019","unstructured":"Liu, Z. et al. Tumor vasculatures: a new target for cancer immunotherapy. Trends Pharm. Sci. 40, 613\u2013623 (2019).","journal-title":"Trends Pharm. Sci."},{"key":"60119_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946861","volume":"13","author":"C Shi","year":"2022","unstructured":"Shi, C. et al. Lenvatinib plus programmed cell death protein-1 inhibitor beyond first-line systemic therapy in refractory advanced biliary tract cancer: a real-world retrospective study in China. Front. Immunol. 13, 946861 (2022).","journal-title":"Front. Immunol."},{"key":"60119_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hep.32548","volume":"77","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Hepatology 77, 65\u201376 (2023).","journal-title":"Hepatology"},{"key":"60119_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi, G. M. et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct. Target Ther. 8, 106 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"60119_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937924","volume":"13","author":"P Fan","year":"2022","unstructured":"Fan, P. et al. Effective low-dose anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Front. Immunol. 13, 937924 (2022).","journal-title":"Front. Immunol."},{"key":"60119_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00262-022-03259-5","volume":"72","author":"S Yuan","year":"2023","unstructured":"Yuan, S. et al. Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients. Cancer Immunol. Immunother. 72, 437\u2013448 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"60119_CR28","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane, C. et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann. Oncol. 30, 1950\u20131958 (2019).","journal-title":"Ann. Oncol."},{"key":"60119_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka, T. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br. J. Cancer 103, 469\u2013474 (2010).","journal-title":"Br. J. Cancer"},{"key":"60119_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/JCO.2023.41.4_suppl.491","volume":"41","author":"AB El-Khoueiry","year":"2023","unstructured":"El-Khoueiry, A. B. et al. IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer. J. Clin. Oncol. 41, 491\u2013491 (2023).","journal-title":"J. Clin. Oncol."},{"key":"60119_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2020.05.014","volume":"73","author":"MG McNamara","year":"2020","unstructured":"McNamara, M. G. et al. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. J. Hepatol. 73, 1109\u20131117 (2020).","journal-title":"J. Hepatol."},{"key":"60119_CR32","first-page":"282","volume":"29","author":"DJ Kuter","year":"2015","unstructured":"Kuter, D. J. Managing thrombocytopenia associated with cancer chemotherapy. Oncology29, 282\u2013294 (2015).","journal-title":"Oncology"},{"key":"60119_CR33","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.2147\/CMAR.S379911","volume":"14","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. A real-world study of optimal treatment with anlotinib first-line therapy in advanced hepatocellular carcinoma. Cancer Manag. Res. 14, 3037\u20133046 (2022).","journal-title":"Cancer Manag. Res."},{"key":"60119_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37030-w","volume":"14","author":"TM Zeng","year":"2023","unstructured":"Zeng, T. M. et al. Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nat. Commun. 14, 1340 (2023).","journal-title":"Nat. Commun."},{"key":"60119_CR35","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1073\/pnas.1919764117","volume":"117","author":"F Mpekris","year":"2020","unstructured":"Mpekris, F. et al. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc. Natl. Acad. Sci. USA 117, 3728\u20133737 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60119_CR36","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang, Y. et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA 109, 17561\u201317566 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60119_CR37","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-19-2179","volume":"26","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade. Clin. Cancer Res. 26, 1712\u20131724 (2020).","journal-title":"Clin. Cancer Res."},{"key":"60119_CR38","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.1158\/0008-5472.CAN-13-1989","volume":"73","author":"Y Huang","year":"2013","unstructured":"Huang, Y., Stylianopoulos, T., Duda, D. G., Fukumura, D. & Jain, R. K. Benefits of vascular normalization are dose and time dependent-letter. Cancer Res. 73, 7144\u20137146 (2013).","journal-title":"Cancer Res."},{"key":"60119_CR39","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-20-0304","volume":"11","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma. Cancer Discov. 11, 1248\u20131267 (2021).","journal-title":"Cancer Discov."},{"key":"60119_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02749-7","volume":"11","author":"F Song","year":"2020","unstructured":"Song, F. et al. Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 11, 573 (2020).","journal-title":"Cell Death Dis."},{"key":"60119_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01971-7","volume":"23","author":"H Li","year":"2024","unstructured":"Li, H. et al. CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib. Mol. Cancer 23, 59 (2024).","journal-title":"Mol. Cancer"},{"key":"60119_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13046-019-1093-3","volume":"38","author":"L Liang","year":"2019","unstructured":"Liang, L. et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\/STAT3\/VEGFA signaling in non-small cell lung cancer cells. J. Exp. Clin. Cancer Res. 38, 71 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"60119_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-022-01249-4","volume":"10","author":"J Sbierski-Kind","year":"2022","unstructured":"Sbierski-Kind, J. et al. Effects of caloric restriction on the gut microbiome are linked with immune senescence. Microbiome 10, 57 (2022).","journal-title":"Microbiome"},{"key":"60119_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41392-022-00918-y","volume":"7","author":"X Xiong","year":"2022","unstructured":"Xiong, X. et al. Cannabis suppresses antitumor immunity by inhibiting JAK\/STAT signaling in T cells through CNR2. Signal Transduct. Target Ther. 7, 99 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"60119_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/ni.2518","volume":"14","author":"BS Reis","year":"2013","unstructured":"Reis, B. S., Rogoz, A., Costa-Pinto, F. A., Taniuchi, I. & Mucida, D. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4(+) T cell immunity. Nat. Immunol. 14, 271\u2013280 (2013).","journal-title":"Nat. Immunol."},{"key":"60119_CR46","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41563-020-00849-5","volume":"20","author":"O Maller","year":"2021","unstructured":"Maller, O. et al. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat. Mater. 20, 548\u2013559 (2021).","journal-title":"Nat. Mater."},{"key":"60119_CR47","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jnci\/djk091","volume":"99","author":"KS Panageas","year":"2007","unstructured":"Panageas, K. S., Ben-Porat, L., Dickler, M. N., Chapman, P. B. & Schrag, D. When you look matters: the effect of assessment schedule on progression-free survival. J. Natl. Cancer Inst. 99, 428\u2013432 (2007).","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60119-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60119-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60119-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:15:49Z","timestamp":1757207749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60119-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60119"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60119-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4557891\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article the affiliation 'Department of Hepato-Pancreato-Biliary & Gastric Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR China' was incorrectly assigned to Jieer Ying and has been removed. In addition, affiliation 1 was given as 'Wenzhou Medical University, Wenzhou, Zhejiang, PR China' and affiliation 2 was given as 'Department of Hepato-Pancreato-Biliary & Gastric Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR China', but should have been affiliations 2 and 1, respectively. The original article has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5559"}}